Table 3.

Univariate and multivariable models for “MRI activity”

Independent variable	Univariate analysis		Multivariable analysis*
	OR (95% CI)	P value	OR (95% CI)	P value
Sex	1.560 (0.648–3.758)	0.321
Age (years)	0.977 (0.940–1.016)	0.252
Disease duration (years)	0.901 (0.828–0.980)	0.015	0.904 (0.824–0.992)	0.034
N. of DMTs before OCR	0.794 (0.575–1.098)	0.161
EDSS score before infusion A	0.722 (0.525–0.992)	0.055
Patients with relapses in the year before infusion A	1.499 (.427–5.269)	0.528
Patients with MRI activity in the year before infusion A	1.427 (0.579–3.521)	0.440
Time on OCR therapy (from start to infusion A, months)	1.018 (0.979–1.059)	0.370
EID	3.32 (1.127–9.970)	0.030	5.373 (1.203–24.001)	0.028
CD19 + B-cell depletion rate before infusion A	1.428 (0.550–3.702)	0.464
CD19 + B-cell depletion rate before infusion B	0.914 (0.306–2.735)	0.873
CD19 + B-cell depletion rate before infusion C	0.338 (0.100–0.890)	0.045	0.197 (0.046–0.846)	0.029

OR odds ratio, DMTs disease modifying therapies, EID extended interval dosing, EDSS expanded disability status scale, MRI magnetic resonance imaging, N number, OCR ocrelizumab, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2

^*R² 0.6